AU6502199A - Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer - Google Patents

Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Info

Publication number
AU6502199A
AU6502199A AU65021/99A AU6502199A AU6502199A AU 6502199 A AU6502199 A AU 6502199A AU 65021/99 A AU65021/99 A AU 65021/99A AU 6502199 A AU6502199 A AU 6502199A AU 6502199 A AU6502199 A AU 6502199A
Authority
AU
Australia
Prior art keywords
diagnosis
treatment
nucleic acids
prostate cancer
expression analysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65021/99A
Other languages
English (en)
Inventor
Kyle J. Macbeth
Andrew W. Shyjan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/163,759 external-priority patent/US6872811B1/en
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU6502199A publication Critical patent/AU6502199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU65021/99A 1998-09-30 1999-09-30 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer Abandoned AU6502199A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16415998A 1998-09-30 1998-09-30
US09164159 1998-09-30
US09/163,759 US6872811B1 (en) 1998-09-30 1998-09-30 HRPCa9 and HRPCa10 nucleic acids and polypeptides
US09163759 1998-10-30
PCT/US1999/022535 WO2000018961A2 (fr) 1998-09-30 1999-09-30 Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate

Publications (1)

Publication Number Publication Date
AU6502199A true AU6502199A (en) 2000-04-17

Family

ID=26859918

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65021/99A Abandoned AU6502199A (en) 1998-09-30 1999-09-30 Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Country Status (5)

Country Link
EP (1) EP1117836A2 (fr)
JP (1) JP2002531061A (fr)
AU (1) AU6502199A (fr)
CA (1) CA2344550A1 (fr)
WO (1) WO2000018961A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
WO2000012758A1 (fr) 1998-09-02 2000-03-09 Diadexus Llc Nouveau procede de diagnostic, de surveillance, de classification par stades, d'imagerie et de traitement de divers cancers
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6355430B1 (en) 1998-12-24 2002-03-12 Millennium Pharmaceuticals, Inc. Diagnostic and screening methods employing KIAA0101
WO2000065067A2 (fr) * 1999-04-23 2000-11-02 University Of Washington Polynucleotides, polypeptides specifiques a la prostate, et leurs procedes d'utilisation
MXPA02012605A (es) 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
DK1299727T3 (da) * 2000-07-12 2009-06-15 Agensys Inc Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
CA2429722A1 (fr) 2000-11-28 2002-06-06 Wyeth Analyse de l'expression des acides nucleiques fkbp et polypeptides utiles dans le diagnostic et le traitement du cancer de la prostate
US7037652B2 (en) 2000-11-28 2006-05-02 Wyeth Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2814598A1 (fr) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Fusion geniques recurrentes dans le cancer de la prostate
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2692793C (fr) 2007-07-06 2014-05-20 The Regents Of The University Of Michigan Rearrangements de genes mipol1 -etv1
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
EP2478120B1 (fr) 2009-09-17 2015-09-02 The Regents Of The University Of Michigan Fusions de gène récurrentes dans le cancer de la prostate
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
JP2012196211A (ja) * 2012-04-10 2012-10-18 Japan Science & Technology Agency 前立腺癌マーカポリペプチド、該ポリペプチドに対する抗体、及び該ポリペプチドを利用した前立腺癌の診断方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187775A1 (fr) * 1994-04-15 1995-10-26 Aaron E. Katz Procede de d'evaluation au niveau moleculaire des stades d'evolution du cancer de la prostate
US5786362A (en) * 1994-06-16 1998-07-28 University Of Miami Method of treating Hormone independent cancer
WO1997027317A1 (fr) * 1996-01-23 1997-07-31 Affymetrix, Inc. Evaluation rapide de difference d'abondance d'acides nucleiques, avec un systeme d'oligonucleotides haute densite
EP0951541B1 (fr) * 1995-07-31 2005-11-30 Urocor, Inc. Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
US5861248A (en) * 1996-03-29 1999-01-19 Urocor, Inc. Biomarkers for detection of prostate cancer
US5783435A (en) * 1996-08-06 1998-07-21 Lamparski; Henry G. Prostate cancer drug screenings
AU6545898A (en) * 1997-03-07 1998-09-22 Reprogen, Inc. Method for identifying hormonally modulated genes

Also Published As

Publication number Publication date
EP1117836A2 (fr) 2001-07-25
WO2000018961A2 (fr) 2000-04-06
CA2344550A1 (fr) 2000-04-06
JP2002531061A (ja) 2002-09-24
WO2000018961A3 (fr) 2001-03-08

Similar Documents

Publication Publication Date Title
HUP0303888A3 (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
GB9925804D0 (en) Biological materials and method useful in the diagnosis and treatment of diseases
AU2002318112B2 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
AU6035299A (en) Interstitial fluid methods and devices for determination of an analyte in the body
AU6502199A (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU8571598A (en) Cancer associated nucleic acids and polypeptides
AU3560399A (en) Tumor associated nucleic acids and uses therefor
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
AU1810899A (en) Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
AU3510200A (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
GB9617616D0 (en) Assaying protein fragments in body fluids
IL155951A0 (en) Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU2001285018A1 (en) Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
MXPA03004577A (es) Analisis de expresion de acidos nucleicos y polipeptidos del inhibidor de diferenciacion utiles en diagnostico y tratamiento de cancer de prostata.
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
IL155954A0 (en) Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
HK1057907A (en) Expression analysis of smarc nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
HK1055997A (en) Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU6278099A (en) Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide
HK1057238A (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
HK1057237A (en) Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
AU5797499A (en) Pkdl nucleic acids, polypeptides, and diagnostic and therapeutic methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase